Clinical Trial Update: Intermediate Dose of IV MTX as CNS Prophylaxis for High Risk DLBCL [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluates intermediate-dose intravenous methotrexate as central nervous system prophylaxis for high-risk diffuse large B-cell lymphoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Central Nervous System Lymphoma
• Diffuse Large B-cell Lymphoma

Drugs mentioned

• METHOTREXATE (METHOTREXATE)

Snippet

Sponsor: Peking Union Medical College Hospital | Conditions: Diffuse Large B Cell Lymphoma, Central Nervous System Lymphoma | Phase 3 | Status: UNKNOWN